Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared on LinkedIn about a recent article by Berkan Kurt et al, published in European Heart Journal:
”Many myths and misconceptions persist regarding the use of the biomarker of inflammation C-reactive protein measured with a highly sensitive assay (hsCRP)
Serial measurements are as stable as cholesterol or blood pressure.
The independent association with future events, independent of traditional risk factors, has been replicated multiple times.
This report of an analysis of almost half a million participants in the UK Biobank should help lay to rest some the concerns commonly voiced about this potent predictor of cardiovascular risk.
Although not causal in cardiovascular events, this excellent analyte can select individuals who can benefit from therapies including statins (JUPITER) and anti-inflammatory interventions (CANTOS)”
Title: C-reactive protein and cardiovascular risk in the general population
Authors: Berkan Kurt , Martin Reugels , Kai M Schneider , Jens Spiesshoefer , Andrea Milzi , Alexander Gombert , Christopher B Fordyce , Florian A Wenzl , Neha J Pagidipati , Viviane Rocha , Marat Fudim , Abhinav Sharma , Michael Lehrke , Hiroaki Shimokawa , Giovanna Liuzzo , Lale Tokgozoglu , Filippo Crea , Thomas F Lüscher , Peter Libby , Paul M Ridker , Nikolaus Marx , Carolin V Schneider , Florian Kahles
Read the Full Article on European Heart Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC